Medigen Biotechnology
Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has complete… Read more
Medigen Biotechnology (3176) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.004x
Based on the latest financial reports, Medigen Biotechnology (3176) has a cash flow conversion efficiency ratio of -0.004x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-18.91 Million) by net assets (NT$4.90 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Medigen Biotechnology - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how Medigen Biotechnology's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Medigen Biotechnology Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medigen Biotechnology ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vieworks Co. Ltd
KQ:100120
|
0.079x |
|
Uniplus Electronics Co Ltd
TWO:5381
|
0.010x |
|
Dinhvu Port Investment Development JSC
VN:DVP
|
0.026x |
|
HKScan Oyj Series A
LSE:0ISM
|
0.009x |
|
Itafos Inc
PINK:MBCF
|
0.086x |
|
Kudelski
SW:KUD
|
-0.143x |
|
DCX Systems Limited
NSE:DCXINDIA
|
0.002x |
|
New Power Plasma Co.Ltd
KQ:144960
|
0.051x |
Annual Cash Flow Conversion Efficiency for Medigen Biotechnology (2003–2024)
The table below shows the annual cash flow conversion efficiency of Medigen Biotechnology from 2003 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$5.04 Billion | NT$37.92 Million | 0.008x | +106.61% |
| 2023-12-31 | NT$5.00 Billion | NT$-569.40 Million | -0.114x | +34.61% |
| 2022-12-31 | NT$6.47 Billion | NT$-1.13 Billion | -0.174x | -316.41% |
| 2021-12-31 | NT$6.43 Billion | NT$517.45 Million | 0.081x | +153.97% |
| 2020-12-31 | NT$4.50 Billion | NT$-671.38 Million | -0.149x | +28.47% |
| 2019-12-31 | NT$2.69 Billion | NT$-560.17 Million | -0.209x | -15.80% |
| 2018-12-31 | NT$2.94 Billion | NT$-529.82 Million | -0.180x | -25.74% |
| 2017-12-31 | NT$3.18 Billion | NT$-455.62 Million | -0.143x | -8.16% |
| 2016-12-31 | NT$3.54 Billion | NT$-468.61 Million | -0.132x | -255.98% |
| 2015-12-31 | NT$3.46 Billion | NT$294.18 Million | 0.085x | -31.58% |
| 2005-12-31 | NT$650.39 Million | NT$80.72 Million | 0.124x | -76.13% |
| 2003-12-31 | NT$856.65 Million | NT$445.46 Million | 0.520x | -- |